BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget. 2015;6:1359-1381. [PMID: 25682197 DOI: 10.18632/oncotarget.3204] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Vandeven N, Nghiem P. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy 2016;8:907-21. [PMID: 27381685 DOI: 10.2217/imt-2016-0009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
2 Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listì A, Vieni S, Gori S, Bazan V, Russo A. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Adv Ther 2019;36:2600-17. [PMID: 31432460 DOI: 10.1007/s12325-019-01057-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 15.7] [Reference Citation Analysis]
3 Bialkowski L, Van der Jeught K, Renmans D, van Weijnen A, Heirman C, Keyaerts M, Breckpot K, Thielemans K. Adjuvant-Enhanced mRNA Vaccines. In: Kramps T, Elbers K, editors. RNA Vaccines. New York: Springer; 2017. pp. 179-91. [DOI: 10.1007/978-1-4939-6481-9_11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zhong M, Zhong C, Hu P, Cui W, Wang G, Gao H, Liu C, Liu Z, Li Z, Li C, Gohda E. Restoration of stemness-high tumor cell-mediated suppression of murine dendritic cell activity and inhibition of tumor growth by low molecular weight oyster polysaccharide. Int Immunopharmacol 2018;65:221-32. [PMID: 30321818 DOI: 10.1016/j.intimp.2018.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Liu JR, Yu CW, Hung PY, Hsin LW, Chern JW. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma. Biochem Pharmacol 2019;163:458-71. [PMID: 30885763 DOI: 10.1016/j.bcp.2019.03.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
6 Corsini LR, Fanale D, Passiglia F, Incorvaia L, Gennusa V, Bazan V, Russo A. Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opin Drug Saf 2018;17:1197-209. [PMID: 30457416 DOI: 10.1080/14740338.2018.1550068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Weiden J, Tel J, Figdor CG. Synthetic immune niches for cancer immunotherapy. Nat Rev Immunol 2018;18:212-9. [PMID: 28853444 DOI: 10.1038/nri.2017.89] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 16.4] [Reference Citation Analysis]
8 Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 2018; 24(34): 3834-3848 [PMID: 30228778 DOI: 10.3748/wjg.v24.i34.3834] [Cited by in CrossRef: 237] [Cited by in F6Publishing: 207] [Article Influence: 59.3] [Reference Citation Analysis]
9 Van der Jeught K, Sun Y, Fang Y, Zhou Z, Jiang H, Yu T, Yang J, Kamocka MM, So KM, Li Y, Eyvani H, Sandusky GE, Frieden M, Braun H, Beyaert R, He X, Zhang X, Zhang C, Paczesny S, Lu X. ST2 as checkpoint target for colorectal cancer immunotherapy. JCI Insight 2020;5:136073. [PMID: 32376804 DOI: 10.1172/jci.insight.136073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
10 Guha I, Bhuniya A, Nandi P, Dasgupta S, Sarkar A, Saha A, Das J, Ganguly N, Ghosh S, Ghosh T, Sarkar M, Ghosh S, Majumdar S, Baral R, Bose A. Neem leaf glycoprotein reverses tumor-induced and age-associated thymic involution to maintain peripheral CD8+ T cell pool. Immunotherapy 2020;12:799-818. [PMID: 32698648 DOI: 10.2217/imt-2019-0168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Van der Jeught K, Van Lint S, Thielemans K, Breckpot K. Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy. Oncoimmunology. 2015;4:e1005504. [PMID: 26155403 DOI: 10.1080/2162402x.2015.1005504] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wang Y, Chu Y, Yue B, Ma X, Zhang G, Xiang H, Liu Y, Wang T, Wu X, Chen B. Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway. Oncotarget 2017;8:23803-16. [PMID: 28423603 DOI: 10.18632/oncotarget.15866] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
13 Shen KY, Liu HY, Yan WL, Wu CC, Lee MH, Leng CH, Liu SJ. Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells. Cancers (Basel) 2020;12:E810. [PMID: 32231003 DOI: 10.3390/cancers12040810] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Zhang X, Kang Z, Li Q, Zhang J, Cheng S, Chang H, Wang S, Cao S, Li T, Li J, Wang Y, Song Y, Yu H. Antigen-adjuvant effects of icariin in enhancing tumor-specific immunity in mastocytoma-bearing DBA/2J mice. Biomed Pharmacother 2018;99:810-6. [PMID: 29710479 DOI: 10.1016/j.biopha.2018.01.139] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
15 Pulliam SR, Pellom ST Jr, Shanker A, Adunyah SE. Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis. Cytokine 2016;84:74-87. [PMID: 27253488 DOI: 10.1016/j.cyto.2016.05.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
16 Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. Front Immunol 2018;9:444. [PMID: 29593717 DOI: 10.3389/fimmu.2018.00444] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 12.0] [Reference Citation Analysis]
17 Goyvaerts C, Breckpot K. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines. J Immunol Res 2015;2015:785634. [PMID: 26583156 DOI: 10.1155/2015/785634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
18 Wang LL, Chen ZS, Zhou WD, Shu J, Wang XH, Jin R, Zhuang LL, Hoda MA, Zhang H, Zhou GP. Down-regulated GATA-1 up-regulates interferon regulatory factor 3 in lung adenocarcinoma. Sci Rep. 2017;7:2551. [PMID: 28566697 DOI: 10.1038/s41598-017-02700-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
19 Stachura J, Wachowska M, Kilarski WW, Güç E, Golab J, Muchowicz A. The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development. Oncoimmunology 2016;5:e1182278. [PMID: 27622039 DOI: 10.1080/2162402X.2016.1182278] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
20 Allen F, Bobanga ID, Rauhe P, Barkauskas D, Teich N, Tong C, Myers J, Huang AY. CCL3 augments tumor rejection and enhances CD8+ T cell infiltration through NK and CD103+ dendritic cell recruitment via IFNγ. Oncoimmunology 2018;7:e1393598. [PMID: 29399390 DOI: 10.1080/2162402X.2017.1393598] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
21 Broos K, Van der Jeught K, Puttemans J, Goyvaerts C, Heirman C, Dewitte H, Verbeke R, Lentacker I, Thielemans K, Breckpot K. Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol Ther Nucleic Acids 2016;5:e326. [PMID: 27327138 DOI: 10.1038/mtna.2016.38] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
22 Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27:1482-1492. [PMID: 27069014 DOI: 10.1093/annonc/mdw168] [Cited by in Crossref: 209] [Cited by in F6Publishing: 214] [Article Influence: 34.8] [Reference Citation Analysis]
23 Lecocq Q, De Vlaeminck Y, Hanssens H, D'Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. Theranostics in immuno-oncology using nanobody derivatives. Theranostics 2019;9:7772-91. [PMID: 31695800 DOI: 10.7150/thno.34941] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 13.7] [Reference Citation Analysis]
24 Sun Z, Wang CY, Lawson DA, Kwek S, Velozo HG, Owyong M, Lai MD, Fong L, Wilson M, Su H, Werb Z, Cooke DL. Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells. Oncotarget. 2017;9:10945-10961. [PMID: 29541388 DOI: 10.18632/oncotarget.23760] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
25 Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol 2018;10:1758835918764628. [PMID: 29623110 DOI: 10.1177/1758835918764628] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
26 Sanegre S, Lucantoni F, Burgos-Panadero R, de La Cruz-Merino L, Noguera R, Álvaro Naranjo T. Integrating the Tumor Microenvironment into Cancer Therapy. Cancers (Basel) 2020;12:E1677. [PMID: 32599891 DOI: 10.3390/cancers12061677] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
27 De Vlaeminck Y, Lecocq Q, Giron P, Heirman C, Geeraerts X, Bolli E, Movahedi K, Massa S, Schoonooghe S, Thielemans K, Goyvaerts C, Van Ginderachter JA, Breckpot K. Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages. J Control Release 2019;299:107-20. [PMID: 30797866 DOI: 10.1016/j.jconrel.2019.02.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
28 Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listì A, Maragliano R, Vincenzi B, Calò V, Iovanna JL, Bazan V, Russo A. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? Cell Immunol 2019;343:103753. [PMID: 29395859 DOI: 10.1016/j.cellimm.2018.01.013] [Cited by in Crossref: 68] [Cited by in F6Publishing: 77] [Article Influence: 17.0] [Reference Citation Analysis]
29 Clappaert EJ, Murgaski A, Van Damme H, Kiss M, Laoui D. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy. Front Immunol 2018;9:2250. [PMID: 30349530 DOI: 10.3389/fimmu.2018.02250] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
30 Van Hoecke L, Verbeke R, Dewitte H, Lentacker I, Vermaelen K, Breckpot K, Van Lint S. mRNA in cancer immunotherapy: beyond a source of antigen. Mol Cancer 2021;20:48. [PMID: 33658037 DOI: 10.1186/s12943-021-01329-3] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
31 Lorenzo C, Pérez-chacón G, Garaulet G, Mallorquín Z, Zapata JM, Rodríguez A. Efficient expression of bioactive murine IL12 as a self-processing P2A polypeptide driven by inflammation-regulated promoters in tumor cell lines. Cancer Gene Ther 2015;22:542-51. [DOI: 10.1038/cgt.2015.53] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
32 Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y, Li Y, Wan C, So KM, Liu D, Frieden M, Fang Y, Mosley AL, He X, Zhang X, Sandusky GE, Liu Y, Meroueh SO, Zhang C, Wijeratne AB, Huang C, Ji G, Lu X. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clin Invest 2021;131:146832. [PMID: 33830945 DOI: 10.1172/JCI146832] [Reference Citation Analysis]
33 Tsui A, Edmondson L, Julius J. An Evaluation of the Use of Corticosteroids for the Management of Immune-Mediated Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. J Adv Pract Oncol 2021;12:137-45. [PMID: 34109046 DOI: 10.6004/jadpro.2021.12.2.2] [Reference Citation Analysis]
34 Moyes KW, Lieberman NA, Kreuser SA, Chinn H, Winter C, Deutsch G, Hoglund V, Watson R, Crane CA. Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy. Hum Gene Ther 2017;28:200-15. [PMID: 27758144 DOI: 10.1089/hum.2016.060] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
35 Adams J, Duffy K, Moore M, Yang J. Cancer Immunotherapy—An Emerging Field That Bridges Oncology and Immunology Research. Comprehensive Medicinal Chemistry III. Elsevier; 2017. pp. 357-94. [DOI: 10.1016/b978-0-12-409547-2.12400-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Miao L, Guo S, Lin CM, Liu Q, Huang L. Nanoformulations for combination or cascade anticancer therapy. Adv Drug Deliv Rev 2017;115:3-22. [PMID: 28624477 DOI: 10.1016/j.addr.2017.06.003] [Cited by in Crossref: 115] [Cited by in F6Publishing: 96] [Article Influence: 23.0] [Reference Citation Analysis]
37 Tobouti PL, Bolt R, Radhakrishnan R, de Sousa SCOM, Hunter KD. Altered Toll-like receptor expression and function in HPV-associated oropharyngeal carcinoma. Oncotarget 2018;9:236-48. [PMID: 29416610 DOI: 10.18632/oncotarget.18959] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
38 Sakellariou C, Elhage O, Papaevangelou E, Giustarini G, Esteves AM, Smolarek D, Smith RA, Dasgupta P, Galustian C. Prostate cancer cells enhance interleukin-15-mediated expansion of NK cells. BJU Int 2020;125:89-102. [PMID: 31392791 DOI: 10.1111/bju.14893] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
39 Salah A, Wang H, Li Y, Ji M, Ou WB, Qi N, Wu Y. Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications. Front Cell Dev Biol 2021;9:686544. [PMID: 34262904 DOI: 10.3389/fcell.2021.686544] [Reference Citation Analysis]
40 Ishii H, Vodnala SK, Achyut BR, So JY, Hollander MC, Greten TF, Lal A, Yang L. miR-130a and miR-145 reprogram Gr-1+CD11b+ myeloid cells and inhibit tumor metastasis through improved host immunity. Nat Commun 2018;9:2611. [PMID: 29973593 DOI: 10.1038/s41467-018-05023-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
41 Savanur MA, Weinstein-Marom H, Gross G. Implementing Logic Gates for Safer Immunotherapy of Cancer. Front Immunol 2021;12:780399. [PMID: 34804073 DOI: 10.3389/fimmu.2021.780399] [Reference Citation Analysis]
42 Bermúdez-Morales VH, Fierros-Zarate G, García-Meléndrez C, Alcocer-Gonzalez JM, Morales-Ortega A, Peralta-Zaragoza O, Torres-Poveda K, Burguete-García AI, Hernández-Márquez E, Madrid-Marina V. In vivo Antitumor Effect of an HPV-specific Promoter driving IL-12 Expression in an HPV 16-positive Murine Model of Cervical Cancer. J Cancer 2016;7:1950-9. [PMID: 27877210 DOI: 10.7150/jca.15536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
43 Hulett TW, Fox BA, Messenheimer DJ, Marwitz S, Moudgil T, Afentoulis ME, Wegman KW, Ballesteros-merino C, Jensen SM. Future Research Goals in Immunotherapy. Surgical Oncology Clinics of North America 2019;28:505-18. [DOI: 10.1016/j.soc.2019.02.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Saxena M, Balan S, Roudko V, Bhardwaj N. Towards superior dendritic-cell vaccines for cancer therapy. Nat Biomed Eng 2018;2:341-6. [PMID: 30116654 DOI: 10.1038/s41551-018-0250-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]